In Re Lorazepam & Clorazepate Antitrust Litigation

289 F.3d 98, 351 U.S. App. D.C. 223, 52 Fed. R. Serv. 3d 930, 2002 U.S. App. LEXIS 9120, 2002 WL 975722
CourtCourt of Appeals for the D.C. Circuit
DecidedMay 14, 2002
Docket01-7163
StatusPublished
Cited by81 cases

This text of 289 F.3d 98 (In Re Lorazepam & Clorazepate Antitrust Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals for the D.C. Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Lorazepam & Clorazepate Antitrust Litigation, 289 F.3d 98, 351 U.S. App. D.C. 223, 52 Fed. R. Serv. 3d 930, 2002 U.S. App. LEXIS 9120, 2002 WL 975722 (D.C. Cir. 2002).

Opinion

Opinion for the Court filed by Circuit Judge ROGERS.

ROGERS, Circuit Judge:

This appeal presents for the first time in this circuit the threshold question of when interlocutory review of a class certification decision is appropriate under Federal Rule of Civil Procedure 23(f). We take the opportunity to offer general guidance on the scope of our discretion under Rule 23(f) in considering the petition for Rule 23(f) review by Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., UDL Laboratories, Inc., Profarmaco S.r.L, Cambrex Corporation, and GYMA Laboratories of America, Inc. (collectively “Mylan”), of the district court’s certification of a class of direct purchasers of the generic anti-anxiety drugs lorazepam and clorazepate from Mylan or UDL. Mylan contends that the district court erred in ruling that despite the Federal Trade Commission’s (“FTC”) procurement, of a settlement against Mylan on behalf of a class of indirect purchasers, a class of direct purchasers had antitrust standing under Illinois Brick Co. v. Illinois, 431 U.S. 720, 97 S.Ct. 2061, 52 L.Ed.2d 707 (1977), and, in the alternative that the certified class consists of both direct and indirect purchasers in violation of Illinois Brick. We conclude that interlocutory appeal pursuant to Rule 23(f) -typically is appropriate in three circumstances: (1) when there is a death-knell situation for either the plaintiff or defendant that is independent of the merits of the underlying claims, coupled with a class certification decision by the district court that is questionable, taking into account the district court’s discretion over class certification; (2) when the certification decision presents an unsettled and fundamental issue *100 of law relating to class actions, important both to the specific litigation and generally, that is likely to evade end-of-the-case review; and (3) when the district court’s class certification decision is manifestly erroneous. Applying these standards we deny Mylan’s petition for interlocutory review.

I.

The class action now pending in the district court was preceded by two lawsuits brought by the FTC and several States’ Attorneys General against Mylan that were ultimately consolidated and ended in a settlement. On December 21, 1998, the FTC filed suit, pursuant to §§ 5 and 13(b) of the Federal Trade Commission Act (“FTC Act”), 15 U.S.C. §§ 45, 53(b), against Mylan, Cambrex, Profarma-co, and GYMA Laboratories, seeking in-junctive and equitable relief, including disgorgement of $120 million plus interest. FTC v. Mylan Labs., Inc., 62 F.Supp.2d 25, 32, 34 (D.D.C.1999). The amended complaint alleged that the defendants had engaged in unfair methods of competition in violation of § 5(a) of the FTC Act, 15 U.S.C. § 45(a), by Mylan’s entering into exclusive licensing agreements with the other defendants, allowing Mylan to control the supply of the active pharmaceutical ingredients (“API”) for generic lorazep-am and clorazepate tablets so that Mylan could increase the price of these generic drugs. On December 22, 1998, the Attorneys General of ten States, later joined by an additional 22 States and the District of Columbia, brought suit against the same defendants and SST Corporation, seeking equitable relief and treble damages for violations of §§ 1 and 2 of the Sherman Act, 15 U.S.C. §§ 1, 2, and various State antitrust laws. Mylan, 62 F.Supp.2d at 32; see also In re Lorazepam & Cloraze-pate Antitrust Litig., 205 F.R.D. 369, 373 (D.D.C.2002). As to the FTC, the district court denied the defendants’ motion to dismiss, which argued that the district court lacked subject matter jurisdiction because the FTC was not authorized to seek either monetary relief or a permanent injunction in an antitrust case. Mylan, 62 F.Supp.2d at 35-37. As to the States, the district court partially granted the defendants’ motion to dismiss, inter alia, narrowing the States’ federal claims to claims under § 4 of the Clayton Act for direct purchases and limiting restitution and disgorgement on behalf of indirect purchasers on a State-by-State basis. Id. at 37-53; see also FTC v. Mylan Labs., Inc., 99 F.Supp.2d 1, 4-10 (D.D.C.1999). Subsequently, the parties entered into a settlement agreement, which the district court approved on February 1, 2002. Mylan, 205 F.R.D. at 402. The settlement agreement provided, in part, that Mylan would pay disgorgement in the amount of $71,782,017 to satisfy the consumer claims in the States’ lawsuit and $28,217,983 to satisfy the States’ agency claims. The settlement agreement also provided that the FTC, States, State agencies, and consumers who did not exclude themselves from the settlement, would release their claims against the defendants.

On August 16, 1999, the Judicial Panel on Multidistrict Litigation transferred to the United States District Court for the District of Columbia a Northern District of Illinois lawsuit pending against Mylan. This lawsuit was consolidated, on March 9, 2000, with a lawsuit brought by St. Charles Rehabilitation Center against Mylan. The named plaintiffs in the consolidated action were Advocate Health Care, St. Charles Hospital and Rehabilitation Center, Dik Drug Company, and Harvard Pilgrim Health Care, and they sought class certification as direct purchasers of lorazepam and clorazepate. The amended complaint alleged that Mylan had engaged in price *101 fixing and monopolization in violation of §§ 1 and 2 of the Sherman Act, and the plaintiffs sought treble damages pursuant to § 4 of the Clayton Act. Mylan moved to dismiss the complaint pursuant to Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6), on the ground that the plaintiffs’ proposed class of direct purchasers lacked antitrust standing to assert their claims. In Illinois Brick, the Supreme Court held that, with narrow exceptions, only direct purchasers may recover damages for illegal overcharges under § 4 of the Clayton Act. Illinois Brick, 431 U.S. at 746-47, 97 S.Ct. at 2074-75. Essentially, Mylan argued that the usual direct purchaser rule of Illinois Brick should not apply because the FTC had won a monetary recovery for the benefit of a class of indirect consumer purchasers pursuant to § 13(b) of the FTC Act for alleged antitrust violations, and to allow both purchaser classes to obtain relief would undermine the policy rationales behind Illinois Brick. In the alternative, Mylan opposed the class certification arguing, inter alia, that the class consisted of direct and indirect purchasers in violation of Illinois Brick's direct purchaser rule. On July 2, 2001, the district court denied the motion to dismiss, and, in accord with the plaintiffs’ request, certified the following class:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Albert Pickett, Jr. v. City of Cleveland, OH
140 F.4th 300 (Sixth Circuit, 2025)
Crowe v. Federal Bureau of Prisons
District of Columbia, 2025
Stallard v. Goldman Sachs Group, Inc.
District of Columbia, 2024
In re: Valerie White
64 F.4th 302 (D.C. Circuit, 2023)
Katie Van v. Llr, Inc.
61 F.4th 1053 (Ninth Circuit, 2023)
Samma v. U.S. Department of Defense
District of Columbia, 2020
Pierce v. Yale University
District of Columbia, 2019
Gary Johnson v. Commission on Presidential De
869 F.3d 976 (D.C. Circuit, 2017)
In re: Herman Brewer
D.C. Circuit, 2017
Harrington v. Sessions
863 F.3d 861 (D.C. Circuit, 2017)
Steele v. United States
159 F. Supp. 3d 73 (District of Columbia, 2016)
Robb v. Connecticut Board of Veterinary Medicine
157 F. Supp. 3d 130 (D. Connecticut, 2016)
In Re: District of Columbia
792 F.3d 96 (D.C. Circuit, 2015)

Cite This Page — Counsel Stack

Bluebook (online)
289 F.3d 98, 351 U.S. App. D.C. 223, 52 Fed. R. Serv. 3d 930, 2002 U.S. App. LEXIS 9120, 2002 WL 975722, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-lorazepam-clorazepate-antitrust-litigation-cadc-2002.